TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24130358

Group type: EXPERIMENTAL
Intervention: Salsalate 3.5 g/day
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 21356021

Group type: EXPERIMENTAL
Intervention: Stannous chloride/sodium fluoride dentifrice (SnCl(2)/NaF, blend-a-med(®) Pro Expert)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice (NaF, Sensodyne(®) ProNamel(™))
Number of subjects: 27
Study: 19709676

Group type: EXPERIMENTAL
Intervention: Tysabri (Natalizumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poisson-type regressions for count data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for time to relapse
Number of subjects: 0
Study: 16566033

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a with ribavirin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a without ribavirin (control)
Number of subjects: 29
Study: 15982963

Group type: EXPERIMENTAL
Intervention: Out-of-Program service contact Days (OD) during Treatment (DT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Out-of-Program service contact Days (OD) at 3 months (3-M)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Out-of-Program services between 3 and 9 months post-treatment
Number of subjects: 88
Study: 11728816

Group type: EXPERIMENTAL
Intervention: Apocynin (3 ml of 0.5 mg/ml) inhaled 2 times before and 6 times after O(3) exposure
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 7
Study: 9041330

Group type: EXPERIMENTAL
Intervention: HIV-infected subjects with <200 CD4 cells/microL
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: HIV-infected subjects with >= 200 CD4 cells/microL
Number of subjects: 142

Group type: COMPARATOR
Intervention: Non-HIV-infected controls
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: HIV-infected subjects
Number of subjects: 142
Study: 7877064

Group type: EXPERIMENTAL
Intervention: Screening group (N = 4691)
Number of subjects: 9300

Group type: COMPARATOR
Intervention: Control group (N = 4619)
Number of subjects: 9300
Study: 3350281

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Cimetidine (600 mg twice daily)
Number of subjects: 169
Study: 31559587

Group type: EXPERIMENTAL
Intervention: Right pericardial window (RPW)
Number of subjects: 120
Study: 30110007

Group type: EXPERIMENTAL
Intervention: Ulinastatin (2×10^4 U/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (50 mL)
Number of subjects: 40
Study: 27717299

Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily)
Number of subjects: 553
Study: 24099637

Group type: EXPERIMENTAL
Intervention: Levodopa (L-Dopa; 100 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 22562746

Group type: EXPERIMENTAL
Intervention: Linear periodization (LP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Daily undulating periodization (DUP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 28
Study: 19373103

Group type: EXPERIMENTAL
Intervention: Very deep sclerectomy with collagen implant (VDSCI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Deep sclerectomy with collagen implant (DSCI)
Number of subjects: 48
Study: 18835931

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (25 ng . kg(‐1) . min(‐1))
Number of subjects: 12
Study: 15043569

Group type: EXPERIMENTAL
Intervention: 100 microg lenograstim daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 250 microg lenograstim daily
Number of subjects: 33
Study: 11355564

Group type: EXPERIMENTAL
Intervention: Triple-dose albendazole (400 mg for 3 consecutive days) plus praziquantel (40 mg/kg) plus iron supplementation (ferrous fumarate 200 mg weekly for 10 weeks)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg) plus praziquantel (40 mg/kg)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Triple-dose albendazole (400 mg for 3 consecutive days) plus praziquantel (40 mg/kg)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control group (no anthelmintic treatment)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Regular 6-monthly anthelmintic treatment
Number of subjects: 428
Study: 9626461

Group type: EXPERIMENTAL
Intervention: Etanidazole (dose levels between 3 and 5.5 g/m2/day, total doses of 12, 16, 20, and 22 g/m2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Etanidazole (16 g/m2 dose level)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Etanidazole
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-dose ICE (ifosfamide, carboplatin, etoposide)
Number of subjects: 55
Study: 8142225

Group type: EXPERIMENTAL
Intervention: Low-protein formula (P:E ratio 5.6%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control protein formula (P:E ratio 10.4%)
Number of subjects: 24
Study: 3144513

Group type: EXPERIMENTAL
Intervention: Budesonide (one-dose pretreatment)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Budesonide (4 weeks pretreatment)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (one-dose pretreatment)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Terbutaline (one-dose pretreatment)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Histamine challenge
Number of subjects: 13
Study: 29220704

Group type: EXPERIMENTAL
Intervention: Heavier peers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27197868

Group type: EXPERIMENTAL
Intervention: Ranibizumab injections
Number of subjects: 2227
Study: 25545856

Group type: EXPERIMENTAL
Intervention: Morning assessment of cold pain threshold (in seconds)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Morning assessment of cold pain threshold (in °C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Morning assessment of cold pain intensity
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Morning assessment of cold pain tolerance
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Morning assessment of heat pain threshold
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Morning assessment of heat pain intensity
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mechanical pain parameters
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dynamic pain paradigms (temporal summation and conditioned pain modulation)
Number of subjects: 48
Study: 23807156

Group type: EXPERIMENTAL
Intervention: Elvitegravir once daily
Number of subjects: 702

Group type: COMPARATOR
Intervention: Raltegravir twice daily
Number of subjects: 702
Study: 20653670

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg once daily) + Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily) in patients with pre-treatment scores >18
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily) in second phase
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg once daily) + Placebo in second phase
Number of subjects: 96
Study: 18089770

Group type: EXPERIMENTAL
Intervention: Single intravenous doses of PC-SOD (40-160 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of PC-SOD (80 mg for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single 80 mg dose of PC-SOD
Number of subjects: 0
Study: 16513919

Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention (4 education classes and individual counseling sessions)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (routine outpatient services, maintain usual lifestyle)
Number of subjects: 70
Study: 12735413

Group type: EXPERIMENTAL
Intervention: Continuous midwifery care
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 51
Study: 11002872

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 32
Study: 9186076

Group type: EXPERIMENTAL
Intervention: Fosinopril (n = 14)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lisinopril (n = 13)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Furosemide (added after 6 weeks if BP goal not achieved)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fosinopril and Lisinopril (combined with furosemide)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fosinopril and Lisinopril (in blacks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fosinopril and Lisinopril (in nonblacks)
Number of subjects: 27
Study: 8262083

Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no graduated compression stockings)
Number of subjects: 80
Study: 3911700

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oxycone-papaverine 5+50 mg
Number of subjects: 51
Study: 29762909

Group type: EXPERIMENTAL
Intervention: Dichlorphenamide, single doses of 25‐400 mg followed by 50‐800 mg/day for 10 doses.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dichlorphenamide, up to 28 titrated doses from 100‐800 mg/day (Cohort F).
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cohorts A, B, and C (doses of 25-400 mg and 50-800 mg/day).
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cohort F (safety analysis only).
Number of subjects: 36
Study: 29171071

Group type: EXPERIMENTAL
Intervention: Web-based support plus standard care (n=83)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard care (n=91)
Number of subjects: 174
Study: 27063319

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil at effect‐site concentration of 1.5 ng/mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 24486089

Group type: EXPERIMENTAL
Intervention: Telaprevir plus peginterferon/ribavirin therapy
Number of subjects: 265
Study: 22482335

Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily for 8 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 55
Study: 20579335

Group type: EXPERIMENTAL
Intervention: Brief cognitive behaviour therapy (CBT) for anxiety disorders
Number of subjects: 3962

Group type: EXPERIMENTAL
Intervention: Brief cognitive behaviour therapy (CBT) for depression
Number of subjects: 3962

Group type: EXPERIMENTAL
Intervention: Brief cognitive behaviour therapy (CBT) for mixed anxiety and depression
Number of subjects: 3962

Group type: EXPERIMENTAL
Intervention: Counselling for depression and mixed anxiety and depression
Number of subjects: 3962

Group type: EXPERIMENTAL
Intervention: Problem solving therapy (PST) for depression and mixed anxiety and depression
Number of subjects: 3962
Study: 17270528

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Other antihypertensive drugs (control)
Number of subjects: 22
Study: 12781273

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 41

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 41
Study: 10787112

Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Number of subjects: 1918

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 1918

Group type: COMPARATOR
Intervention: Placebo at home
Number of subjects: 1918

Group type: EXPERIMENTAL
Intervention: Placebo in hospital
Number of subjects: 1918
Study: 9109134

Group type: EXPERIMENTAL
Intervention: Once daily ceftriaxone plus amikacin
Number of subjects: 265

Group type: COMPARATOR
Intervention: Three times daily ceftazidime plus amikacin
Number of subjects: 265
Study: 8260292

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitrogen
Number of subjects: 20
Study: 3980055

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study: 30183329

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (Method A)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo auricular acupressure (Method B)
Number of subjects: 83
Study: 28219102

Group type: EXPERIMENTAL
Intervention: Acute antioxidant supplementation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Antioxidant supplementation
Number of subjects: 19
Study: 24999252

Group type: EXPERIMENTAL
Intervention: Implantable hemodynamic monitor (IHM)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Ongoing knowledge of hemodynamic data
Number of subjects: 550
Study: 24124952

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) control
Number of subjects: 6

Group type: COMPARATOR
Intervention: Open-loop (OL) control
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) control in euglycemic range (CL-Eu)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) control in hyperglycemic range (CL-Hyper)
Number of subjects: 6
Study: 22048173

Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine (Cervarix®, GlaxoSmithKline Biologicals, Months 0, 1, 6)
Number of subjects: 1106

Group type: COMPARATOR
Intervention: HPV-6/11/16/18 vaccine (Gardasil® Merck & Co., Inc., Months 0, 2, 6)
Number of subjects: 1106
Study: 19118466

Group type: EXPERIMENTAL
Intervention: Tubeless PCNL with externalized ureteral catheter
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tubeless PCNL with Double-J placement
Number of subjects: 46
Study: 17715457

Group type: EXPERIMENTAL
Intervention: Vision and touch
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vision and no touch
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: No vision and touch
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: No vision and no touch
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control subjects (CS)
Number of subjects: 18
Study: 15090013

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus intralesional meglumine antimoniate (MA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (MA)
Number of subjects: 400
Study: 10915072

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) therapy
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 157
Study: 8960472

Group type: EXPERIMENTAL
Intervention: Implanted cardioverter-defibrillator
Number of subjects: 196

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 196
Study: 1388172

Group type: EXPERIMENTAL
Intervention: Various treatment methods for lateral epicondylitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo effect of all treatments
Number of subjects: 0
Study: 3894482

Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 7

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 7
Study: 31272465

Group type: EXPERIMENTAL
Intervention: OMT + CSWT
Number of subjects: 72

Group type: COMPARATOR
Intervention: OMT + sham procedure
Number of subjects: 72
Study: 29654420

Group type: COMPARATOR
Intervention: Surgical stripping
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Laser setting 1 (4.5 W, 50 Hz, 100% water, 80% air, 60 μs, 800 μm Tip; MZ8)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Laser setting 2 (2.5 W, 50 Hz, 20% water, 40% air, 700 μs, 800 μm Tip; MZ8)
Number of subjects: 33
Study: 27466981

Group type: EXPERIMENTAL
Intervention: Preoperative faces with lesions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postoperative faces with lesions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Faces with large peripheral lesions (LP)
Number of subjects: 120
Study: 24293167

Group type: EXPERIMENTAL
Intervention: Oral vitamin C (2 g before surgery and 500 mg twice daily for 5 days after surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no vitamin C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral vitamin C
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 23733308

Group type: EXPERIMENTAL
Intervention: SOC plus mefloquine (250 mg for 3 days, then 250 mg weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SOC plus mefloquine
Number of subjects: 0
Study: 20886185

Group type: COMPARATOR
Intervention: Enoxaparin (30 mg BID starting 12-24 hours postoperatively)
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: TAK-442 10 mg BID
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: TAK-442 20 mg BID
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: TAK-442 40 mg QD
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: TAK-442 40 mg BID
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: TAK-442 80 mg QD
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: TAK-442 80 mg BID
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: TAK-442 (all doses except 10 and 20 mg BID)
Number of subjects: 1038
Study: 18634152

Group type: EXPERIMENTAL
Intervention: High-dose iloprost (up to 2 ng/kg body weight per minute)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-dose iloprost (0.5 ng/kg body weight per minute)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both high-dose and low-dose iloprost
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-dose iloprost
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-dose iloprost
Number of subjects: 50
Study: 16671423

Group type: EXPERIMENTAL
Intervention: B‐ICH group
Number of subjects: 149

Group type: COMPARATOR
Intervention: U‐ICH group
Number of subjects: 149
Study: 14637388

Group type: EXPERIMENTAL
Intervention: Tumour marker guided treatment (salvage treatment)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional treatment (after radiological confirmation of metastases)
Number of subjects: 109
Study: 11359261

Group type: EXPERIMENTAL
Intervention: One-stage MS fixtures
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Two-stage MS fixtures
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: One-stage TPS fixtures
Number of subjects: 29

Group type: COMPARATOR
Intervention: TPS implants
Number of subjects: 29
Study: 8773865

Group type: EXPERIMENTAL
Intervention: Group 1 (visual evaluation of thumb movements)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group 2 (no visual evaluation of thumb movements)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 1370236

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal polypeptide (VIP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 20
Study: 31758850

Group type: EXPERIMENTAL
Intervention: Dulaglutide (DU) 1.5 mg
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Dulaglutide (DU) 0.75 mg
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Glimepiride (GLIM) or Insulin Glargine (GLAR)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Insulin Glargine (GLAR)
Number of subjects: 1147
Study: 30565017

Group type: EXPERIMENTAL
Intervention: Magnesium and Vitamin E co-supplementation (250 mg/day magnesium plus 400 mg/day vitamin E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28655596

Group type: EXPERIMENTAL
Intervention: Lower fat, higher carbohydrate diet (fat 20%, carbohydrate 66% energy)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Moderate fat, moderate carbohydrate diet (fat 30%, carbohydrate 56% energy)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Higher fat, lower carbohydrate diet (fat 40%, carbohydrate 46% energy)
Number of subjects: 307
Study: 26374138

Group type: EXPERIMENTAL
Intervention: Intervention protocol (sevoflurane‐remifentanil‐rocuronium‐ropivacaine)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control protocol (isoflurane‐sufentanil‐atracurium‐levobupivacaine)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Patients with IRT > 20 min (n=190)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Patients with IRT ≤ 20 min
Number of subjects: 352
Study: 23414120

Group type: EXPERIMENTAL
Intervention: Erythropoietin intravenous (EIV) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Erythropoietin subcutaneous (ESC) group
Number of subjects: 100
Study: 21719898

Group type: EXPERIMENTAL
Intervention: Yogurt supplement (YOG; n = 15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Isoenergetic sucrose beverage (CONT; n = 14)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 21481244

Group type: EXPERIMENTAL
Intervention: Clinical management of bipolar disorder (non-interventional, longitudinal study)
Number of subjects: 3000
Study: 17209212

Group type: EXPERIMENTAL
Intervention: Nutritional supplements for cancer prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term prospective cohort studies
Number of subjects: 0
Study: 16281923

Group type: EXPERIMENTAL
Intervention: Valacyclovir treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High disease activity
Number of subjects: 0
Study: 12049443

Group type: EXPERIMENTAL
Intervention: Child therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Parent/teacher training
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined child therapy and parent/teacher training
Number of subjects: 61
Study: 9855591

Group type: COMPARATOR
Intervention: Intravenous opioids (meperidine)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (compliant patients)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Intravenous opioids (compliant patients)
Number of subjects: 318
Study: 7794572

Group type: EXPERIMENTAL
Intervention: Finapres (FIN)
Number of subjects: 15